Berberine-Based Heterogeneous Linear Supramolecules Neutralized the Acute Nephrotoxicity of Aristolochic Acid by the Self-Assembly Strategy
Source abstract
Abstract
Aristolochic acid (AA) has been reported to cause a series of health problems, including aristolochic acid nephropathy and liver cancer. However, AA-containing herbs are highly safe in combination with berberine (Ber)-containing herbs in traditional medicine, suggesting the possible neutralizing effect of Ber on the toxicity of AA. In the present study, in vivo systematic toxicological experiments performed in zebrafish and mice showed that the supramolecule self-assembly formed by Ber and AA significantly reduced the toxicity of AA and attenuated AA-induced acute kidney injury. Ber and AA can self-assemble into linear heterogenous supramolecules (A–B) via electrostatic attraction and π–π stacking, with the hydrophobic groups outside and the hydrophilic groups inside during the drug combination practice. This self-assembly strategy may block the toxic site of AA and hinder its metabolism. Meanwhile, A–B linear supramolecules did not disrupt the homeostasis of gut microflora as AA did. RNA-sequence analysis, immunostaining, and western blot of the mice kidney also showed that A–B supramolecules almost abolished the acute nephrotoxicity of AA in the activation of the immune system and tumorigenesis-related pathways.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nephrotoxicity and Medicinal Plants · Drug-Induced Hepatotoxicity and Protection · Berberine and alkaloids research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China
School of Life Science, Beijing University of Chinese Medicine, Beijing 100029, China
Funding
Project commissioned by National Medical Products Administration
References (39)
Show source-provided references
1. 10.1016/j.jep.2004.06.01010.1016/j.jep.2004.06.010 ↗
2. 10.1136/bmj.e400010.1136/bmj.e4000 ↗
3. 10.1126/scitranslmed.aan644610.1126/scitranslmed.aan6446 ↗
4. 10.1038/s41577-019-0198-410.1038/s41577-019-0198-4 ↗
5. 10.1016/j.metop.2020.10004010.1016/j.metop.2020.100040 ↗
6. 10.1038/ncomms848910.1038/ncomms8489 ↗
7. 10.1021/jacs.8b0455610.1021/jacs.8b04556 ↗
8. 10.1021/jacs.8b0491210.1021/jacs.8b04912 ↗
9. 10.1021/acsami.5b0534710.1021/acsami.5b05347 ↗
10. 10.1039/c3cc38419e10.1039/c3cc38419e ↗
11. 10.1002/chem.20080037410.1002/chem.200800374 ↗
12. 10.1021/jp806992f10.1021/jp806992f ↗
13. 10.2147/ijn.s903510.2147/ijn.s9035 ↗
14. Wang H. · World J. Tradit. Chin. Med. · 2020 · 15 · 1102
15. 10.1021/jp076850j10.1021/jp076850j ↗
16. 10.3390/ijerph1507140810.3390/ijerph15071408 ↗
17. 10.1016/j.carbpol.2017.10.06710.1016/j.carbpol.2017.10.067 ↗
18. 10.1021/acsnano.9b0134610.1021/acsnano.9b01346 ↗
19. 10.1016/j.apsb.2019.12.01410.1016/j.apsb.2019.12.014 ↗
20. 10.1021/acsami.9b1772210.1021/acsami.9b17722 ↗
21. 10.1038/ncomms649310.1038/ncomms6493 ↗
22. 10.1038/s41392-020-00456-510.1038/s41392-020-00456-5 ↗
23. Wu J. · J. Tradit. Chin. Med. · 2012 · 14 · 39
24. 10.1038/ki.2008.12910.1038/ki.2008.129 ↗
25. 10.3390/ijms2103115710.3390/ijms21031157 ↗
26. 10.1038/ki.2011.37110.1038/ki.2011.371 ↗
27. 10.1038/s41598-018-23565-210.1038/s41598-018-23565-2 ↗
28. 10.3390/biom1001001110.3390/biom10010011 ↗
29. 10.1038/nature1247710.1038/nature12477 ↗
30. 10.1093/carcin/bgm08210.1093/carcin/bgm082 ↗
31. 10.1016/j.jgg.2015.03.00310.1016/j.jgg.2015.03.003 ↗
32. 10.1007/s00109-014-1180-z10.1007/s00109-014-1180-z ↗
33. 10.5483/bmbrep.2019.52.9.19310.5483/bmbrep.2019.52.9.193 ↗
34. 10.1155/2019/374505110.1155/2019/3745051 ↗
35. 10.1038/nmeth.331710.1038/nmeth.3317 ↗
36. 10.1038/nmeth.192310.1038/nmeth.1923 ↗
37. 10.1038/nbt.312210.1038/nbt.3122 ↗
38. 10.12688/f1000research.15398.310.12688/f1000research.15398.3 ↗
39. 10.1093/nar/gky90010.1093/nar/gky900 ↗